At yesterday's J.P. Morgan Healthcare Conference NVIDIA announced new partnerships to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI. The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.

These solutions include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring and operations. AI agents, AI instruments and AI robots will help address the $3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars.

IQVIA, the world's leading provider of clinical research services, commercial insights and healthcare intelligence, is working with NVIDIA to build custom foundation models and agentic AI workflows that can accelerate research, clinical development and access to new treatments. AI applications trained on the organization's vast healthcare-specific information and guided by its deep domain expertise will help the industry boost the efficiency of clinical trials and optimize planning for the launch of therapies and medical devices—ultimately improving patient outcomes.

Operating in over 100 countries, IQVIA has built the largest global healthcare network and is uniquely connected to the ecosystem with the most comprehensive and granular set of information, analytics and technologies in the industry. Announced today at the J.P. Morgan Conference in San Francisco, IQVIA's collection of models, AI agents and reference workflows will be developed with the NVIDIA AI Foundry platform for building custom models, allowing IQVIA's thousands of pharmaceutical, biotech and medical device customers to benefit from NVIDIA's agentic AI capabilities and IQVIA's technologies, life sciences information and expertise.

"This year, every industry will become a technology industry," NVIDIA founder and CEO Jensen Huang told attendees last Wednesday during the annual J.P. Morgan Healthcare Conference. "You can now recognize and learn the language of almost anything with structure, and you can translate it to anything with structure—so text-protein, protein-text," Huang said in a fireside chat with Martin Chavez, partner and vice chairman of global investment firm Sixth Street Partners and board chair of Recursion, a biopharmaceutical company. "This is the generative AI revolution."

The conversation, which took place at the historic San Francisco Mint, followed a presentation at the J.P. Morgan conference Monday by Kimberly Powell, NVIDIA's VP of healthcare. In her talk, Powell announced that Recursion is the first hosting partner to offer a foundation model through the NVIDIA BioNeMo cloud service, which is advancing into beta this month. She also said that Amgen, one of the first companies to employ BioNeMo, plans to advance drug discovery with generative AI and NVIDIA DGX SuperPOD—and that BioNeMo is used by a growing number of techbio companies, pharmas, AI software vendors and systems integrators. Among them are Deloitte, Innophore, Insilico Medicine, OneAngstrom, Recursion and Terray Therapeutics.

Scientific researchers need massive computational resources that can support exploration wherever it happens. Whether they're conducting groundbreaking pharmaceutical research, exploring alternative energy sources or discovering new ways to prevent financial fraud, accessible state-of-the-art AI computing resources are key to driving innovation. This new model of computing can solve the challenges of generative AI and power the next wave of innovation. Cambridge-1, a supercomputer NVIDIA launched in the U.K. during the pandemic, has powered discoveries from some of the country's top healthcare researchers. The system is now becoming part of NVIDIA DGX Cloud to accelerate the pace of scientific innovation and discovery - across almost every industry.

As a cloud-based resource, it will broaden access to AI supercomputing for researchers in climate science, autonomous machines, worker safety and other areas, delivered with the simplicity and speed of the cloud, ideally located for the U.K. and European access. DGX Cloud is a multinode AI training service that makes it possible for any enterprise to access leading-edge supercomputing resources from a browser. The original Cambridge-1 infrastructure included 80 NVIDIA DGX systems; now it will join with DGX Cloud, to allow customers access to world-class infrastructure.